N/A
Completed N=68
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Source: ClinicalTrials.gov NCT01399190 ↗Enrolled (actual)
68
Serious AEs
3.2%
Results posted
Sep 2016
Primary outcomePrimary: Progression-free Survival — 7.000 months
Summary
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
7.000 | — |
| SECONDARY Response Rate (Tumor Assessments According to RECIST) |
48.4; 6.7; 41.7 | — |
| SECONDARY Percentage of Participants With Adverse Events |
74.6 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Treatment in accordance with current Summary of Product Characteristics and local guidelines
Exclusion Criteria
- Contraindications according to current Summary of Product Characteristics and local guidelines
Data sourced from ClinicalTrials.gov (NCT01399190). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.